These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 25609178)

  • 21. Clinical significance of radiological patterns of HRCT and their association with macrophage activation in dermatomyositis.
    Zuo Y; Ye L; Liu M; Li S; Liu W; Chen F; Lu X; Gordon P; Wang G; Shu X
    Rheumatology (Oxford); 2020 Oct; 59(10):2829-2837. PubMed ID: 32065646
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical effects of direct hemoperfusion using a polymyxin B-immobilized fiber column in clinically amyopathic dermatomyositis-associated rapidly progressive interstitial pneumonias.
    Okabayashi H; Ichiyasu H; Hirooka S; Akaike K; Kojima K; Jodai T; Sakamoto Y; Ideguchi H; Hamada S; Yoshida C; Hirosako S; Okamoto S; Kohrogi H
    BMC Pulm Med; 2017 Oct; 17(1):134. PubMed ID: 29065861
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Association of Serum Soluble CD163 with Polymyositis and Dermatomyositis, Especially in Anti-MDA5 Antibody-positive Cases.
    Kawasumi H; Katsumata Y; Nishino A; Hirahara S; Kawaguchi Y; Kuwana M; Yamanaka H
    J Rheumatol; 2018 Jul; 45(7):947-955. PubMed ID: 29657141
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pre-treatment ferritin level and alveolar-arterial oxygen gradient can predict mortality rate due to acute/subacute interstitial pneumonia in dermatomyositis treated by cyclosporine a/glucocorticosteroid combination therapy: a case control study [corrected].
    Isoda K; Takeuchi T; Kotani T; Hata K; Shoda T; Ishida T; Yoshida S; Kimura Y; Makino S; Hanafusa T
    PLoS One; 2014; 9(2):e89610. PubMed ID: 24586910
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Serum cytokine profiles of patients with interstitial lung disease associated with anti-CADM-140/MDA5 antibody positive amyopathic dermatomyositis.
    Takada T; Aoki A; Asakawa K; Sakagami T; Moriyama H; Narita I; Sato S
    Respir Med; 2015 Sep; 109(9):1174-80. PubMed ID: 26187000
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pirfenidone in patients with rapidly progressive interstitial lung disease associated with clinically amyopathic dermatomyositis.
    Li T; Guo L; Chen Z; Gu L; Sun F; Tan X; Chen S; Wang X; Ye S
    Sci Rep; 2016 Sep; 6():33226. PubMed ID: 27615411
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Correlation between disease activity and serum ferritin in clinically amyopathic dermatomyositis with rapidly-progressive interstitial lung disease: a case report.
    Yamada K; Asai K; Okamoto A; Watanabe T; Kanazawa H; Ohata M; Ohsawa M; Hirata K
    BMC Res Notes; 2018 Jan; 11(1):34. PubMed ID: 29338781
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prognostic factors for myositis-associated interstitial lung disease.
    Fujisawa T; Hozumi H; Kono M; Enomoto N; Hashimoto D; Nakamura Y; Inui N; Yokomura K; Koshimizu N; Toyoshima M; Shirai T; Yasuda K; Hayakawa H; Suda T
    PLoS One; 2014; 9(6):e98824. PubMed ID: 24905449
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Serum YKL-40 level is associated with severity of interstitial lung disease and poor prognosis in dermatomyositis with anti-MDA5 antibody.
    Jiang L; Wang Y; Peng Q; Shu X; Wang G; Wu X
    Clin Rheumatol; 2019 Jun; 38(6):1655-1663. PubMed ID: 30739212
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Elevated Erythrocyte Sedimentation Rate Is Predictive of Interstitial Lung Disease and Mortality in Dermatomyositis: a Korean Retrospective Cohort Study.
    Go DJ; Lee EY; Lee EB; Song YW; Konig MF; Park JK
    J Korean Med Sci; 2016 Mar; 31(3):389-96. PubMed ID: 26955239
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Serum neopterin as well as ferritin, soluble interleukin-2 receptor, KL-6 and anti-MDA5 antibody titer provide markers of the response to therapy in patients with interstitial lung disease complicating anti-MDA5 antibody-positive dermatomyositis.
    Nishioka A; Tsunoda S; Abe T; Yoshikawa T; Takata M; Kitano M; Matsui K; Nakashima R; Hosono Y; Ohmura K; Mimori T; Sano H
    Mod Rheumatol; 2019 Sep; 29(5):814-820. PubMed ID: 30449228
    [No Abstract]   [Full Text] [Related]  

  • 32. [Clinical features and risk factors associated with interstitial lung disease in patients with classic dermatomyositis or clinical amyopathic dermatomyositis].
    Lin H; Liang Y; Wang Y; Cen XM; Yin G; Xie QB
    Sichuan Da Xue Xue Bao Yi Xue Ban; 2013 Sep; 44(5):805-9. PubMed ID: 24325117
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical and HRCT features of amyopathic dermatomyositis associated with interstitial lung disease: A retrospective study of 128 patients with connective tissue disease-related interstitial lung disease.
    Wu T; Zhou H; Xu S; Deng Z; Zhang Y; Ding Q
    Am J Med Sci; 2023 May; 365(5):429-436. PubMed ID: 36521530
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Anti-MDA5 antibody, ferritin and IL-18 are useful for the evaluation of response to treatment in interstitial lung disease with anti-MDA5 antibody-positive dermatomyositis.
    Gono T; Sato S; Kawaguchi Y; Kuwana M; Hanaoka M; Katsumata Y; Takagi K; Baba S; Okamoto Y; Ota Y; Yamanaka H
    Rheumatology (Oxford); 2012 Sep; 51(9):1563-70. PubMed ID: 22589330
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Gottron Papules and Gottron Sign with Ulceration: A Distinctive Cutaneous Feature in a Subset of Patients with Classic Dermatomyositis and Clinically Amyopathic Dermatomyositis.
    Cao H; Xia Q; Pan M; Zhao X; Li X; Shi R; Zhou M; Ding X; Kuwana M; Zheng J
    J Rheumatol; 2016 Sep; 43(9):1735-42. PubMed ID: 27307530
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The efficacy of calcineurin inhibitors for the treatment of interstitial lung disease associated with polymyositis/dermatomyositis.
    Kurita T; Yasuda S; Amengual O; Atsumi T
    Lupus; 2015 Jan; 24(1):3-9. PubMed ID: 25297551
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Early pulmonary involvement of anti-CADM-140 autoantibody-positive rapidly progressive interstitial lung disease preceding typical cutaneous symptoms.
    Tamai K; Tachikawa R; Otsuka K; Ueda H; Hosono Y; Tomii K
    Intern Med; 2014; 53(21):2515-9. PubMed ID: 25366013
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Risk Factors of Respiratory Failure in the Dermatomyositis Patients with Interstitial Lung Disease].
    Zhang SH; Peng Y; Xie QB; Yin G; Yan B
    Sichuan Da Xue Xue Bao Yi Xue Ban; 2018 Mar; 49(2):188-194. PubMed ID: 29737058
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy of plasma exchange in anti-MDA5-positive dermatomyositis with interstitial lung disease under combined immunosuppressive treatment.
    Shirakashi M; Nakashima R; Tsuji H; Tanizawa K; Handa T; Hosono Y; Akizuki S; Murakami K; Hashimoto M; Yoshifuji H; Ohmura K; Mimori T
    Rheumatology (Oxford); 2020 Nov; 59(11):3284-3292. PubMed ID: 32276271
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Short-term and long-term outcomes of interstitial lung disease in polymyositis and dermatomyositis: a series of 107 patients.
    Marie I; Hatron PY; Dominique S; Cherin P; Mouthon L; Menard JF
    Arthritis Rheum; 2011 Nov; 63(11):3439-47. PubMed ID: 21702020
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.